Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

This is some text inside of a div block.
This is some text inside of a div block.

Problem Tech Solves

Tech Brief

Epilepsy is one of the most common neurological conditions, affecting more than 3.4 million Americans and more than 65 million people worldwide. 10% of the population will experience a seizure at some point in their life - often requiring multi-day monitoring to uncover answers. Epilepsy can be hard to diagnose due to the intermittent and infrequent nature of symptoms - standard tests are too short. Many other conditions are easily confused - especially cardiac conditions. There is a 30% misdiagnosis rate of epilepsy, and distinguishing these conditions requires data. Yet hospitals are bottlenecks; monitoring is costly in hospitals, so resources are limited and waitlists extensive. Physicians are forced to make decisions, often without evidence. By shifting clinical monitoring from the hospital to the home, Seer addresses a large unmet need for accurate, objective data, with a far superior patient experience. Week-long brain and heart monitoring at home means a much faster path to diagnoses and better patient outcomes. As Australia’s largest provider of epilepsy diagnostic services, Seer serves more patients than all Australia’s hospitals combined. Having demonstrated the effectiveness of ambulant diagnostic monitoring for epilepsy in Australia and with FDA 510(K) clearance confirmed, Seer now offers a new pathway to diagnosis for Americans with epilepsy - one that does not require a hospital stay and one that will give doctors the data they need to more accurately diagnose epilepsy and episodic disorders.

Tech Differentiators

SUPERIOR PATIENT EXPERIENCE: - Seer’s unparalleled patient experience eliminates the need for a 7-day hospital stay. - Home-based testing means patients can move freely within their home, surrounded by family and friends. This natural home-environment also contributes to the capture of more accurate, real-world events. - The wearable ‘Seer Sense’ hardware is light, has a battery life of up to 10 days and allows unparalleled freedom of movement during testing. The quick connect feature enables patients to shower during multi-day monitoring, improving patient experience and satisfaction dramatically. ACCESSIBILITY: - Seer makes ultra long-term monitoring more accessible. Patients who otherwise could not access hospital-based studies (whether due to wait lists, location or caring responsibilities) are now able to be monitored at home. SUPERIOR RESULTS & HIGHLY SCALABLE: - Seer offers superior diagnostic yield compared to hospital and competitor offerings, leading to higher accuracy (less misdiagnosis) and strong doctor satisfaction. - Seer’s vertically integrated model is also highly scalable due to the use of AI powered monitoring and reporting and cloud-enabled data review. The use of machine learning and Seer’s highly personalised algorithm maximises report throughput and minimises human review required. GLOBALLY LEADING R&D: - Seer are pioneers in the development of medical technology for at-home monitoring and our research is advancing global understanding of epilepsy. - Seer’s world-first non-invasive seizure risk forecasting capabilities (launched in 2022), allow patients to track, monitor and forecast their seizure risk. - Seer has 3 registered patents related to seizure forecasting across the USA and Australia, in addition to 4 registered designs and 75+ trademarks.


Seer has demonstrated success for both economic and clinical outcomes in its home market of Australia. Since launching in 2017, Seer has become Australia’s largest provider of epilepsy diagnostic services, serving more patients than all Australia’s hospitals combined. Seer has monitored 11,800+ Australians who would have required 50,000+ days in Australian hospitals, diverting ~95 bed years from the Australian hospital system to reduce patient wait times dramatically. This has saved the Australian healthcare system an estimated $131 million. (Note: under embargo until further notice): In the US context, the FDA study for Seer Home was completed at the Mayo Clinic in Rochester in 2022. This study included testing of the Seer Home devices with 15 American subjects confirming Seer Home’s usability. Seer and the Mayo Clinic are now in the midst of exploring a further pilot study, in which they will roll out Seer’s home-based video EEG monitoring to clinics across the US in the Mayo Clinic Care Network. This will open the pathway to serving hundreds of thousands of Americans in the years ahead.

Why Us